Sandostatin therapy in sarcoidosis
Recruiting
- Conditions
- Sarcoidosis, sandostatinSarcoïdose, sandostatine
- Registration Number
- NL-OMON25865
- Lead Sponsor
- Erasmus Medical Center, Department of Internal Medicine.
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Age above 18 years with obtained written consent
2. Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
Exclusion Criteria
1. Corticosteroid use up to three months prior of trial
2. Chronic renal failure defined as a GFR below 50%
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main endpoint is the change in uptake on somatostatin receptor scan.
- Secondary Outcome Measures
Name Time Method The secondary endpoint is the composite clinical score using the following parameters: blood test (ESR, CRP, full blood count, lysozyme, ACE, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, sIL-2R), quality of life (RAND-36) and when applicable lung function test (FVC, DLCO) and skin evaluation.